PYC Therapeutics Limited (PYCXF PINK) stock market data APIs
$1.2419
0(0%)
as of October 30, 2026
Try our APIs with
free plan!
PYC Therapeutics Limited Financial Data Overview
Price chart is built with
Anychart
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Prev. Close
1.2419
Open
1.2419
High
1.2419
Low
1.2419
52 wk Range
0.8462-1.8
Market Cap
1 231 M
Shares Outstanding
985 M
Revenue
25 994 K
Beta
1.054
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PYC Therapeutics Limited data using free add-ons & libraries
Get PYC Therapeutics Limited Fundamental Data
PYC Therapeutics Limited Fundamental data includes:
- Net Revenue: 25 994 K
- EBITDA: -56 591 320
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get PYC Therapeutics Limited Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PYC Therapeutics Limited News
New
Exploring 3 High Growth Tech Stocks in Australia
The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending i...
Exploring High Growth Tech Stocks in Australia Featuring Three Prominent Companies
As the Australian market edges towards the holiday season, it is experiencing a slight dip, largely attributed to profit-taking as major global indices approach record highs. In this context, high gro...
ASX Growth Stocks With High Insider Confidence For December 2025
As the Australian market winds down for the holiday season, with a slight dip attributed to profit-taking and global indices nearing record highs, investors are reflecting on their portfolios and cons...
3 ASX Growth Stocks With Insider Ownership Up To 38%
The Australian market has experienced a mix of reactions recently, with the IT sector making gains despite broader concerns about inflation and materials sector performance. In such an environment, gr...
Get PYC Therapeutics Limited fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.